Azitra to present ex‑vivo skin model data showing 56% wrinkle reduction at BIO‑Europe
Azitra, Inc. will present data on its ATR‑COSF topical filaggrin protein at the BIO‑Europe conference in Cologne on 10 Nov 2026. The ex‑vivo human skin models showed a 56% reduction in wrinkles and improved elasticity after a single application of the 4% formulation. The company also said the first‑in‑human study of ATR‑COSF is expected to yield initial results by year‑end and that its ATR‑04 trial has been expanded to include patients with rashes from KRAS and MEK inhibitors.
Why it matters
The presentation highlights early efficacy signals for a cosmetic‑focused biotherapeutic, which could broaden Azitra’s pipeline and attract partnership interest. The expanded ATR‑04 trial increases the addressable patient pool for the rash treatment, potentially enhancing future market opportunity.
Key facts
- 1Azitra will present ATR‑COSF results at BIO‑Europe in Cologne, Germany on 10 Nov 2026 at 4:45 pm CET. prnewswire.com
- 2In an ex‑vivo human torso skin model, ATR‑COSF achieved a 56% reduction in wrinkles from baseline. prnewswire.com
- 3The 4% ATR‑COSF formulation also improved elasticity and wrinkle depth compared with vehicle in a second ex‑vivo model at 48 hours. prnewswire.com
- 4Azitra expects initial results from the first‑in‑human ATR‑COSF study by year‑end 2026. prnewswire.com
- 5The Phase 1/2 ATR‑04 trial was expanded in Oct 2026 to include patients with rashes from KRAS and MEK inhibitors, in addition to EGFR inhibitors and NF1 patients on MEK inhibitors. prnewswire.com
- 6Approximately 85,000 U.S. patients receive KRAS or MEK inhibitor treatment annually, and about 220,000 receive EGFR inhibitor treatment annually. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.